摘要
目的:探究重组人脑钠肽治疗慢性心力衰竭急性失代偿性重症患者的治疗效果。方法:选取我院2016年5月至2017年8月期间收治的120例慢性心力衰竭急性失代偿性重症(ADHF)患者为研究对象,将其随机分成两组,各60例。对照组使用米力农治疗,观察组使用重组人脑钠肽治疗,比较两组的治疗效果。结果:两组患者治疗前的周身水肿、呼吸困难、肺部啰音评分相较无较大的差异,治疗后两组评分均有改善但观察组的改善程度比对照组好;观察组的治疗总有效率高于对照组;观察组的不良反应发生率低于对照组,两组间比较差异较大(P<0.05)有统计学意义。结论:重组人脑钠肽治疗慢性心力衰竭急性失代偿性重症患者的效果良好,能改善患者呼吸困难等症状及心功能,对纠正心衰症状效果显著。
Objective: To investigate the therapeutic effect of recombinant human brain natriuretic peptide on acute decompensated severe patients with chronic heart failure. Methods: 120 patients with acute decompensated(ADHF)from May 2016 to August 2017 were randomly divided into two groups: 60 cases each. The control group was treated with milrinone and the observation group with recombinant human brain natriuretic peptide. Results: There was no significant difference in peripheral edema, dyspnea and lung rale score between the two groups before treatment. The total effective rate of treatment in the observation group was higher than that in the control group, the incidence of adverse reactions in the observation group was lower than that in the control group, and the difference between the two groups was significant(P<0.05). Conclusion: Recombinant human brain natriuretic peptide is effective in the treatment of acute decompensated severe patients with chronic heart failure. It can improve the symptoms of dyspnea and cardiac function, and has a significant effect on correcting the symptoms of heart failure.
作者
徐晓波
吴田田
XU Xiao-bo;WU Tian-tian(Coronary Heart Disease intensive Care Unit,Xuchang City Central Hospital,Xuchang Henan 461000,China;Department of Cardiology,Xuchang Hospital,Xuchang Henan 461000,China)
出处
《药品评价》
CAS
2019年第5期31-33,43,共4页
Drug Evaluation
关键词
重组人脑钠肽
慢性心力衰竭急性失代偿性
治疗效果
Recombinant Human Brain Natriuretic Peptide
Acute Decompensation of Chronic Heart Failure
Therapeutic Effect
